93 related articles for article (PubMed ID: 7533826)
1. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy.
Cubeddu LX; O'Connor DT; Parmer RJ
J Clin Oncol; 1995 Mar; 13(3):681-7. PubMed ID: 7533826
[TBL] [Abstract][Full Text] [Related]
2. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
[TBL] [Abstract][Full Text] [Related]
3. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
4. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.
Cubeddu LX
Oncology; 1996 Jun; 53 Suppl 1():18-25. PubMed ID: 8692546
[TBL] [Abstract][Full Text] [Related]
5. The role of serotonin as a mediator of emesis induced by different stimuli.
du Bois A; Kriesinger-Schroeder H; Meerpohl HG
Support Care Cancer; 1995 Sep; 3(5):285-90. PubMed ID: 8520873
[TBL] [Abstract][Full Text] [Related]
6. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Malave JJ
Br J Cancer; 1992 Jul; 66(1):198-203. PubMed ID: 1379060
[TBL] [Abstract][Full Text] [Related]
7. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
du Bois A; Vach W; Siebert C; Holy R; Ledergerber M; Wechsel U; Kriesinger-Schroeder H
Support Care Cancer; 1997 May; 5(3):212-8. PubMed ID: 9176967
[TBL] [Abstract][Full Text] [Related]
8. Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics.
Cubeddu LX; Hoffmann IS
J Clin Pharmacol; 1993 Aug; 33(8):691-7. PubMed ID: 7691898
[TBL] [Abstract][Full Text] [Related]
9. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.
Alfieri AB; Cubeddu LX
Br J Cancer; 1995 Mar; 71(3):629-32. PubMed ID: 7533519
[TBL] [Abstract][Full Text] [Related]
10. Urinary serotonin metabolite excretion during cisplatin chemotherapy.
Wilder-Smith OH; Borgeat A; Chappuis P; Fathi M; Forni M
Cancer; 1993 Oct; 72(7):2239-41. PubMed ID: 7690681
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
12. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer].
Matsumoto S; Kawasaki Y; Mikami M; Nakamoto M; Tokuyasu H; Kometani Y; Chikumi H; Hitsuda Y; Matsumoto Y; Sasaki T
Gan To Kagaku Ryoho; 1999 Mar; 26(4):535-8. PubMed ID: 10097753
[TBL] [Abstract][Full Text] [Related]
15. Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis.
Fukui H; Yamamoto M; Ando T; Sasaki S; Sato S
Neuropharmacology; 1993 Oct; 32(10):959-68. PubMed ID: 8295718
[TBL] [Abstract][Full Text] [Related]
16. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
17. Serotonin-independent model of cisplatin-induced emesis in the ferret.
Rudd JA; Cheng CH; Naylor RJ
Jpn J Pharmacol; 1998 Nov; 78(3):253-60. PubMed ID: 9869258
[TBL] [Abstract][Full Text] [Related]
18. Effect of cisplatin on the disposition of endogenous serotonin and its main metabolite, 5-hydroxyindole-3-acetic acid, in rats and dogs.
Nakajima Y; Yamamoto K; Yamada Y; Sawada Y; Iga T
Biol Pharm Bull; 1996 Feb; 19(2):318-22. PubMed ID: 8850333
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas.
Bashir S; Gibril F; Ojeaburu JV; Asgharian B; Entsuah LK; Ferraro G; Crafa P; Bordi C; Jensen RT
Aliment Pharmacol Ther; 2002 Jul; 16(7):1367-82. PubMed ID: 12144588
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity.
Minami M; Endo T; Hirafuji M; Hamaue N; Liu Y; Hiroshige T; Nemoto M; Saito H; Yoshioka M
Pharmacol Ther; 2003 Aug; 99(2):149-65. PubMed ID: 12888110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
